PHILADELPHIA, April 1, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing ...
Carisma Therapeutics (CARM)’ Board of Directors has approved and the Company intends to proceed with the voluntary delisting of its common stock from The Nasdaq Stock Market and the deregistration of ...
PARIS--(BUSINESS WIRE)--Regulatory News: During its meeting of 15 October, the Board of Directors of Carmila (Paris:CARM) took note of the resignation of Mrs Claire du Payrat. The entire Board of ...
Further to the selection process launched by Carmila's (Paris:CARM) Board of Directors on 16 June 2020, and following the opinion of the Compensation and Nomination Committee, the extraordinary Board ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback